L
LB Pharmaceuticals Inc D
D
LBRX
26.530
USD
1.08
(4.24%)
Market Closed
Volume
12,455
EPS
-4
Div Yield
-
P/E
-8
Market Cap
760,743,160
Title: LB Pharmaceuticals Inc
Sector: Healthcare
Industry: Biotechnology
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatmentof neuropsychiatric diseases, including schizophrenia.